Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non–Small-Cell Lung Cancer Patients with EGFR Mutations

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090

EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373

The DNA Damage Response: Ten Years After

Harper, J. W., & Elledge, S. J. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.11.015 · Cited by 1,705

Detection of Mutations in EGFR in Circulating Lung-Cancer Cells

Maheswaran, S., Sequist, L. V., Nagrath, S., Ulkus, L., Brannigan, B., Collura, C. V., Inserra, E., Diederichs, S., Iafrate, A. J., Bell, D. W., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800668 · Cited by 1,617

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

Sequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228

Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

Katayama, R., Shaw, A. T., Khan, T. M., Mino-Kenudson, M. A., Solomon, B., Halmos, B., Jessop, N. A., Wain, J. C., Yeo, A. T., Benes, C. H., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003316 · Cited by 1,337

Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology

Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Chirieac, L. R., D’Amico, T. A., DeCamp, M. M., Dilling, T. J., Dobelbower, M. C., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0050 · Cited by 1,315

ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics

Arteaga, C. L., & Engelman, J. A. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.025 · Cited by 1,048

Non–Small Cell Lung Cancer

_, _. (2008) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2008.0021 · Cited by 737

NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016

Ettinger, D. S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., Cheney, R. T., Chirieac, L. R., D’Amico, T. A., Dilling, T. J., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0031 · Cited by 744

Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling

Hirata, E., Girotti, M. R., Viros, A., Hooper, S., Spencer-Dene, B., Matsuda, M., Larkin, J., Marais, R., & Sahai, E. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.008 · Cited by 593

Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis

Lee, C. K., Brown, C. S. B., Gralla, R. J., Hirsh, V., Thongprasert, S., Tsai, C., Tan, E. H., Ho, J., Chu, D., Zaatar, A., et al. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt072 · Cited by 511

Pretreatment Epidermal Growth Factor Receptor ( EGFR ) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer

Su, K.-Y., Chen, H.-Y., Li, K.-C., Kuo, M.-L., Yang, J. C.-H., Chan, W.-K., Ho, B.-C., Chang, G.-C., Shih, J.-Y., Yu, S.-L., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.3224 · Cited by 499

Non–Small Cell Lung Cancer, Version 6.2015

Ettinger, D. S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., Cheney, R. T., Chirieac, L. R., D’Amico, T. A., Demmy, T. L., et al. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0071 · Cited by 478

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease

Ohashi, K., Maruvka, Y. E., Michor, F., & Pao, W. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.3912 · Cited by 467

Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer

Wu, J.-Y., Yu, C.-J., Chang, Y.-C., Yang, C.-H., Shih, J.-Y., & Yang, P.-C. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3408 · Cited by 463

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

Yang, J. C., Shih, J., Su, W., Hsia, T., Tsai, C., Ou, S. I., Yu, C., Chang, G., Ho, C., Sequist, L. V. D., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70086-4 · Cited by 413

EGFR signaling pathway as therapeutic target in human cancers

Levantini, E., Maroni, G., Re, M. D., & Tenen, D. G. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.04.002 · Cited by 390

New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer

Oxnard, G. R., Arcila, M. E., Chmielecki, J., Ladanyi, M., Miller, V. A., & Pao, W. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2571 · Cited by 359

Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients

Remón, J., Steuer, C. E., Ramalingam, S. S., & Felip, E. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx704 · Cited by 332

Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.

Stewart, E., Tan, S. Z., Liu, G., & Tsao, M. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2014.11.06 · Cited by 314

Genetics and biomarkers in personalisation of lung cancer treatment

Rosell, R., Bivona, T. G., & Karachaliou, N. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61715-8 · Cited by 305

NCCN Guidelines Insights: Kidney Cancer, Version 2.2020

Motzer, R. J., Jonasch, E., Michaelson, M. D., Nandagopal, L., Gore, J. L., George, S., Alva, A., Haas, N., Harrison, M. R., Plimack, E. R., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0054 · Cited by 287

Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients

Karachaliou, N., Gonzalez-Cao, M., Crespo, G., Drozdowskyj, A., Aldeguer, E., Gimenez-Capitan, A., Teixido, C., Molina-Vila, M. A., Viteri, S., De Los Llanos Gil, M., et al. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017749748 · Cited by 285

Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?

Hölzel, M., Bovier, A., & Tüting, T. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3498 · Cited by 275

Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance

Yu, H. A., Suzawa, K., Jordan, E., Zehir, A., Ni, A., Kim, R., Kris, M. G., Hellmann, M. D., Li, B. T., Somwar, R., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2961 · Cited by 259

An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy

Wang, Y.-Q., Wang, P., Wang, Y.-T., Yang, G., Zhang, A., & Miao, Z. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00055 · Cited by 251

First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer

Greenhalgh, J., Dwan, K. M., Boland, A., Bates, V., Vecchio, F., Dundar, Y., Jain, P., & Green, J. A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010383.pub2 · Cited by 248

Epidermal growth factor receptor mutations in lung adenocarcinoma

Siegelin, M. D., & Borczuk, A. (2013) · Laboratory Investigation · doi:10.1038/labinvest.2013.147 · Cited by 234

The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR -Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial

Costa, C., Molina, M. A., Drozdowskyj, A., Giménez-Capitán, A., Bertran-Alamillo, J., Karachaliou, N., Gervais, R., Massuti, B., Wei, J., Moran, T., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2233 · Cited by 229

Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)

Gelatti, A., Drilon, A. E. D. C., & Santini, F. C. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.09.017 · Cited by 220

Ultra-sensitive detection of the pretreatment EGFR T790M mutation in non-small cell lung cancer patients with an EGFR-activating mutation using droplet digital PCR

Watanabe, M., Kawaguchi, T., Isa, S.-I., Ando, M., Tamiya, A., Kubo, A., Saka, H., Takeo, S., Adachi, H., Tagawa, T., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2151 · Cited by 216

Exosome-Based Detection of EGFR T790M in Plasma from Non–Small Cell Lung Cancer Patients

Castellanos-Rizaldos, E., Grimm, D. G., Tadigotla, V. R., Hurley, J. D., Healy, J., Neal, P. L., Sher, M., Venkatesan, R., Karlovich, C., Raponi, M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3369 · Cited by 218

Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC

CHAIB-OUKADOUR, I., Karachaliou, N., Pilotto, S., Servat, J. C., Cai, X., Li, X., Drozdowskyj, A., Codony, C., Yang, J. E., Hu, C., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx014 · Cited by 210

Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing

Yu, H. A., Arcila, M. E., Hellmann, M. D., Kris, M. G., Ladanyi, M., & Riely, G. J. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt573 · Cited by 206

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016

Tan, D. S. W., Yom, S. S., Tsao, M. S., Pass, H. I., Kelly, K., Peled, N., Yung, R. C., Wistuba, I. I., Yatabe, Y., Unger, M., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.05.008 · Cited by 201

Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology – Mainland China Subset Analysis of the PIONEER study

Shi, Y., Li, J., Zhang, S., Wang, M., Yang, S., Li, N., Wu, G., Liu, W., Liao, G., Cai, K., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143515 · Cited by 196

Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor‐sensitizing and resistance mutations in the plasma DNA of patients with advanced non–small cell lung cancer during treatment with erlotinib

Sørensen, B. S., Wu, L., Wei, W., Tsai, J., Weber, B., Nexø, E., & Meldgaard, P. (2014) · Cancer · doi:10.1002/cncr.28964 · Cited by 194

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): An international, multicentre, single-arm, phase 2 trial

Rosell, R., Dafni, U., Felip, E., Curioni-Fontecedro, A., Gautschi, O., Peters, S., Massutí, B., Palmero, R., Aix, S. P., Carcereny, E., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30129-7 · Cited by 182

Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non–Small Cell Lung Cancer

Molina‐Vila, M. Á., Bertrán-Alamillo, J., Gascó, A., Mayo‐de‐las‐Casas, C., Sanchez-Ronco, M., Pujantell-Pastor, L., Bonanno, L., Favaretto, A. G., Cardona, A. F., Vergnenégre, A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2391 · Cited by 186

A framework for understanding and targeting residual disease in oncogene-driven solid cancers

Bivona, T. G., & Doebele, R. C. (2016) · Nature Medicine · doi:10.1038/nm.4091 · Cited by 184

Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer

Yochum, Z. A., Cades, J., Wang, H., Chatterjee, S., Simons, B. W., O’Brien, J. P., Khetarpal, S. K., Lemtiri-Chlieh, G., Myers, K. V., Huang, E. H. ‐., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0482-y · Cited by 185

Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors

Jimeno, A., Weiss, G. J., Miller, W. H., Gettinger, S. N., Eigl, B. J., Chang, A. L. S., Dunbar, J., Devens, S., Faia, K., Skliris, G. P., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3654 · Cited by 171

Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer

Jacobsen, K., Bertrán-Alamillo, J., Molina‐Vila, M. Á., Teixidó, C., Karachaliou, N., Pedersen, M. H., Castellví, J., Garzón, M., Codony, C., Codony‐Servat, J., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00450-6 · Cited by 162

Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas

Cortot, A. B., & Jänne, P. A. (2014) · European Respiratory Review · doi:10.1183/09059180.00004614 · Cited by 158

Personalized medicine in lung cancer: what we need to know

Mok, T. S. K. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.126 · Cited by 165

Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non–Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI

Hata, A., Katakami, N., Yoshioka, H., Kaji, R., Masago, K., Fujita, S., Imai, Y., Nishiyama, A., Ishida, T., Nishimura, Y., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000647 · Cited by 150

Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations

Wang, J., Wang, B., Chu, H., & Yao, Y. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s106399 · Cited by 143

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: A new era begins

Remón, J., Morán, T., Majem, M., Reguart, N., Dalmau, E., Márquez-Medina, D., & LIANES, P. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.06.002 · Cited by 137

Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping

Ou, S. I., Young, L., Schrock, A. B., Johnson, A., Klempner, S. J., Zhu, V. W., Miller, V. A., & Ali, S. M. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.09.119 · Cited by 133

EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects

Soria, J., Mok, T. S. K., Cappuzzo, F., & Janne, P. A. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.10.003 · Cited by 131

Quantification and Dynamic Monitoring of EGFR T790M in Plasma Cell-Free DNA by Digital PCR for Prognosis of EGFR-TKI Treatment in Advanced NSCLC

Wang, Z., Chen, R., Wang, S., Zhong, J., Wu, M., Zhao, J., Duan, J., Zhuo, M., An, T., Wang, Y., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110780 · Cited by 130

Screening for Germline EGFR T790M Mutations Through Lung Cancer Genotyping

Oxnard, G. R., Miller, V. A., Robson, M. E., Azzoli, C. G., Pao, W. J., Ladanyi, M., & Arcila, M. E. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318250ed9d · Cited by 130

EGFR first- and second-generation TKIs—there is still place for them in EGFR-mutant NSCLC patients

Karachaliou, N., Fernández-Bruno, M., Bracht, J. W. P., & Rosell, R. (2018) · Translational Cancer Research · doi:10.21037/tcr.2018.10.06 · Cited by 131

EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor

Jia, Y., Juarez, J., Li, J., Manuia, M., Niederst, M. J., Tompkins, C., Timple, N., Vaillancourt, M.-T., Pferdekamper, A. C., Lockerman, E. L., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2581 · Cited by 121

Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC

Agulnik, M., Nelson, Ziehr, & Johnson, J. R. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s23165 · Cited by 121

Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors

Sun, J., Ahn, M., Choi, Y., Ahn, J. S., & Park, K. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.08.023 · Cited by 121

Highly Sensitive Detection of EGFR T790M Mutation Using Colony Hybridization Predicts Favorable Prognosis of Patients with Lung Cancer Harboring Activating EGFR Mutation

Fujita, Y., Suda, K., Kimura, H., Matsumoto, K., Arao, T., Nagai, T., Saijo, N., Yatabe, Y., Mitsudomi, T., & Nishio, K. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182653d7f · Cited by 119

Benchmarking of Mutation Diagnostics in Clinical Lung Cancer Specimens

Querings, S., Altmüller, J., Ansén, S., Zander, T., Seidel, D., Gabler, F., Peifer, M., Markert, E., STEMSHORN, K. C., Timmermann, B., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019601 · Cited by 115

Droplet-Based Digital PCR

Perkins, G., Lu, H., Garlan, F., & Taly, V. (2016) · Advances in clinical chemistry · doi:10.1016/bs.acc.2016.10.001 · Cited by 114

Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence

Troiani, T., Napolitano, S., Della Corte, C. M., Martini, G., Martinelli, E., Morgillo, F., & Ciardiello, F. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000088 · Cited by 104

EGFR mutations in lung cancer: from tissue testing to liquid biopsy

Fenizia, F., Luca, A. D., Pasquale, R., Sacco, A., Forgione, L., Lambiase, M., Iannaccone, A., Chicchinelli, N., Franco, R., Rossi, A., et al. (2015) · Future Oncology · doi:10.2217/fon.15.23 · Cited by 95

Common EGFR -Mutated Subgroups (Del19/L858R) in Advanced Non-Small-Cell Lung Cancer: Chasing Better Outcomes with Tyrosine Kinase Inhibitors

Reguart, N., & Remon, J. (2015) · Future Oncology · doi:10.2217/fon.15.15 · Cited by 91

Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression

Reguart, N., Rosell, R., Cardenal, F., Cardona, A. F., Isla, D., Palmero, R., Morán, T., Rolfo, C. D., Pallarès, M. C., Insa, A., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.02.011 · Cited by 88

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature

Zhou, C., & Yao, L. D. (2015) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.10.002 · Cited by 87

Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma

Lohinai, Z., Hoda, M. A., Fábián, K., Ostoros, G., Rásó, E., Barbai, T., Tı́már, J., Kovalszky, I., Cserepes, M., Rózsás, A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000492 · Cited by 79

Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors

Rolfo, C. D., Giovannetti, E., Hong, D. S., Bivona, T. G., Raez, L. E., Bronte, G., Buffoni, L., Reguart, N., Santos, E. S., Germonpré, P. R., et al. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.05.009 · Cited by 80

High T790M detection rate in TKI-naive NSCLC with EGFR sensitive mutation: truth or artifact?

Ye, X., Zhu, Z.-Z., Zhong, L., Lu, Y., Sun, Y., Yin, X., Yang, Z., Zhu, G., & Ji, Q. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31829f691f · Cited by 79

Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients

Lin, L., & Bivona, T. G. (2012) · Chemotherapy Research and Practice · doi:10.1155/2012/817297 · Cited by 85

Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor

Sakai, K., Horiike, A., Irwin, D. L., Kudo, K., Fujita, Y., Tanimoto, A., Sakatani, T., Saito, R., Kaburaki, K., Yanagitani, N., et al. (2013) · Cancer Science · doi:10.1111/cas.12211 · Cited by 78

Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer

Dienstmann, R., Dosso, S. D., Felip, E., & Tabernero, J. M. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.11.009 · Cited by 77

EGFR T790M resistance mutation in non small-cell lung carcinoma

Denis, M. G., Vallée, A., & Théoleyre, S. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.01.039 · Cited by 76

EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer

Wang, Z., & Fang, S. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s69690 · Cited by 80

Current Approaches in NSCLC Targeting K-RAS and EGFR

Aran, V., & Omerović, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225701 · Cited by 74

Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment

Kuiper, J. L., Hashemi, S. M. S., Thunnissen, E., Snijders, P. J. F., Grünberg, K., Bloemena, E., Sie, D., Postmus, P. E., Heideman, D. A. M., & Smit, E. F. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.372 · Cited by 73

Peripheral Blood for Epidermal Growth Factor Receptor Mutation Detection in Non-Small Cell Lung Cancer Patients

Li, X., Ren, R., Ren, S., Chen, X., Cai, W., Zhou, F., Zhang, Y., Su, C., Zhao, C., Li, J., et al. (2014) · Translational Oncology · doi:10.1016/j.tranon.2014.04.006 · Cited by 74

First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer

Greenhalgh, J., Boland, A., Bates, V., Vecchio, F., Dundar, Y., Chaplin, M., & Green, J. A. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010383.pub3 · Cited by 73

Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer

Ji, W., Choi, C., Rho, J. K., Jang, S. J., Park, Y. S., Chun, S., Kim, W. S., Lee, J., Kim, S., Lee, D. H., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-606 · Cited by 72

Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib ofEGFRmutant advanced lung adenocarcinoma

Bria, E., Pilotto, S., Amato, E., Fassan, M., Novello, S., Peretti, U., Vavalà, T., Kinspergher, S., Righi, L., Santo, A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3727 · Cited by 74

Concurrent Driver Gene Mutations as Negative Predictive Factors in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer

Chen, M., Xu, Y., Zhao, J., Zhong, W., Zhang, L., Bi, Y., & Wang, M. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.03.023 · Cited by 69

Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis

Chen, L.-Y., Molina-Vila, M. A., Ruan, S.-Y., Su, K.-Y., Liao, W.-Y., Yu, K.-L., Ho, C.-C., Shih, J.-Y., Yu, C.-J., Yang, J. C.-H., et al. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.01.019 · Cited by 67

Tumor Burden is Predictive of Survival in Patients With Non–Small-Cell Lung Cancer and With Activating Epidermal Growth Factor Receptor Mutations Who Receive Gefitinib

Park, J. H., Kim, T. M., Keam, B., Jeon, Y. K., Lee, S., Kim, D., Chung, D. H., Kim, Y. T., Kim, Y. W., & Heo, D. S. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.10.007 · Cited by 66

Overcoming drug resistance to receptor tyrosine kinase inhibitors: Learning from lung cancer

Kuwano, M., Sonoda, K., Murakami, Y., Watari, K., & Ono, M. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.03.002 · Cited by 66

Comprehensive molecular screening: from the RT-PCR to the RNA-seq.

Costa, C., Giménez-Capitán, A. A., Karachaliou, N., & Rosell, R. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2013.02.05 · Cited by 74

Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer.

Bordi, P., Re, M. D., Danesi, R., & Tiseo, M. (2015) · PubMed Central · doi:10.3978/j.issn.2218-6751.2015.08.09 · Cited by 66

Mechanisms of resistance to EGFR targeted therapies

Hrustanovic, G., Lee, B. J., & Bivona, T. G. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.23627 · Cited by 67

Survival Outcome Assessed According to Tumor Response and Shrinkage Pattern in Patients with EGFR Mutation–Positive Non–Small-Cell Lung Cancer Treated with Gefitinib or Erlotinib

Takeda, M., Okamoto, I., & Nakagawa, K. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000053 · Cited by 65

BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer

Karachaliou, N., Codony‐Servat, J., Teixidó, C., Pilotto, S., Drozdowskyj, A., Codony, C., Giménez-Capitán, A. A., Molina‐Vila, M. Á., Bertrán-Alamillo, J., Gervais, R., et al. (2015) · Scientific Reports · doi:10.1038/srep17499 · Cited by 65

Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary management

Noronha, V., Rajendra, A., Joshi, A., Patil, V., Menon, N. N., & Prabhash, K. (2019) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_51_19 · Cited by 64

Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective

Jiang, W., Cai, G., Hu, P. C., & Wang, Y. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.04.005 · Cited by 67

Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling

WICKI, A. N., Mandalà, M., Massi, D., Taverna, D., Tang, H., Hemmings, B. A., & Xue, G. (2016) · Physiological Reviews · doi:10.1152/physrev.00024.2015 · Cited by 64

Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib

Tartarone, A., Lazzari, C., Lerose, R., Conteduca, V., Improta, G., Zupa, A., Bulotta, A., Aieta, M., & Gregorc, V. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.05.020 · Cited by 63

The relationship between vagal nerve activity and clinical outcomes in prostate and non-small cell lung cancer patients

Couck, M., van Brummelen, D., Schallier, D. C. C., Grève, J. D., & Gidron, Y. (2013) · Oncology Reports · doi:10.3892/or.2013.2725 · Cited by 62

Drug Resistance to Molecular Targeted Therapy and Its Consequences for Treatment Decisions in Non-Small-Cell Lung Cancer

Spaans, J. N., & Goss, G. D. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00190 · Cited by 57

Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients

Riediger, A. L., Dietz, S., Schirmer, U. B., Meister, M. A., Heinzmann-Groth, I., Schneider, M. A., Muley, T., Thomas, M., & Sültmann, H. (2016) · Scientific Reports · doi:10.1038/srep33505 · Cited by 59

Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never‐smoker women with pulmonary adenocarcinoma

Ren, S., Chen, X., Kuang, P., Zheng, L.-M., Su, C., Li, J., Li, B., Wang, Y., Liu, L., Hu, Q., et al. (2012) · Cancer · doi:10.1002/cncr.27603 · Cited by 57

STAT3 signaling mediates tumour resistance to EGFR targeted therapeutics

Zulkifli, A., Tan, F. H., Putoczki, T. L., Stylli, S. S., & Luwor, R. B. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.01.010 · Cited by 59

Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors and Therapeutic Approaches: An Update

Ahsan, A. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-24223-1_7 · Cited by 56

Meta-analysis of the impact of de novo and acquired EGFR T790M mutations on the prognosis of patients with non-small cell lung cancer receiving EGFR-TKIs

Liu, Y., Sun, L., Xiong, Z., Sun, X., Zhang, S., Ma, J., & Han, C. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s133082 · Cited by 54

Overcoming erlotinib resistance with tailored treatment regimen in patient‐derived xenografts from naïve Asian NSCLC patients

Yang, M., Shan, B., Li, Q., Song, X., Cai, J., Deng, J., Zhang, L., 杜镇建, Lu, J., Chen, T., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27813 · Cited by 53

Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance

Tartarone, A., & Lerose, R. (2015) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465815587820 · Cited by 54

Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC)

Codony, C., Codony‐Servat, J., Karachaliou, N., Molina‐Vila, M. Á., CHAIB-OUKADOUR, I., Ramírez, J. L., Gil, M. D. L. L., Solca, F., Bivona, T. G., & Rosell, R. (2017) · Oncotarget · doi:10.18632/oncotarget.17625 · Cited by 50

EGFR T790M detection rate in lung adenocarcinomas at baseline using droplet digital PCR and validation by ultra-deep next generation sequencing

Lettig, L., Sahnane, N., Pepe, F., Cerutti, R., Albeni, C., Franzi, F., Veronesi, G., Ogliari, F. R., Pastore, A., Tuzi, A., et al. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.09.18 · Cited by 51

Outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) according to the presence of the EGFR T790M mutation and BRCA1 mRNA expression levels in pretreatment biopsies.

Rosell, R., Molina, M. A., Costa, C., Tarón, M., Bertrán-Alamillo, J., Mayo, C., Benlloch, S., Morán, T., Cardenal, F., & Porta, R. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.7514 · Cited by 14

BRCA1, LMO4, and CtIP mRNA Expression in Erlotinib-Treated Non–Small-Cell Lung Cancer Patients with EGFR Mutations

Karachaliou, N., Costa, C., Giménez-Capitán, A. A., Molina‐Vila, M. Á., Bertrán-Alamillo, J., Mayo, C., Massutí, B., Majem, M., Carcereny, E., Morán, T., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31827db621 · Cited by 19

The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR -Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial

Costa, C., Molina, M. A., Drozdowskyj, A., Giménez-Capitán, A., Bertran-Alamillo, J., Karachaliou, N., Gervais, R., Massuti, B., Wei, J., Moran, T., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2233 · Cited by 229

Abstract 1727: Correlation between BRCA1 and LMO4 mRNA expression levels in Erlotinib-treated non small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations

Costa, C., Giménez-Capitán, A. A., Benlloch, S., Tarón, M., Jimeno, J. M., Viteri, S., Gascó, A., Camps, C., Carcereny, E., Massutí, B., et al. (2012) · Cancer Research · doi:10.1158/1538-7445.am2012-1727

Abstract 4112: De novo EGFR T790M mutation modifies outcome to second-line erlotinib in non-small cell lung cancer (NSCLC) according to metastatic site and upfront chemotherapy

Rosell, R., Molina‐Vila, M. Á., Sánchez, J. J., Tarón, M., Benlloch, S., Morán, T., Carcereny, E., Cardenal, F., Massutí, B., & Magrí, I. (2011) · Cancer Research · doi:10.1158/1538-7445.am2011-4112 · Cited by 1